Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 20/20 | 1.00 |
| ▸ | LCK | P06239 | 6/20 | 1.00 |
| ▸ | TXK | P42681 | 6/20 | 1.00 |
| ▸ | SYK | P43405 | 6/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622450 | 0.89 | ITK (0.82) | ITKLCKTXKSYK | |
| SCHEMBL1622213 | 0.87 | ITK (1.00) | ITKLCKTXKSYKPLK4 | |
| SCHEMBL1623389 | 0.84 | ITK (0.72) | ITKLCKTXKSYK | |
| SCHEMBL12747703 | 0.84 | ITK (0.77) | ITKLCKTXKSYK | |
| SCHEMBL1622393 | 0.81 | ITK (0.67) | ITKLCKTXKSYK | |
| SCHEMBL1622709 | 0.80 | ITK (0.72) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1621994 | 0.80 | ITK (0.72) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1622893 | 0.80 | ITK (0.72) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1622620 | 0.79 | ITK (0.65) | ITKLCKTXKSYK | |
| SCHEMBL1620633 | 0.79 | ITK (0.65) | ITKLCKTXKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4115886-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | Pharmacyclics LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | IOVANCE BIOTHERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210121463-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2021-04-29 | — | — | US | disclosed |
| WO-2015084892-A1 | METHODS FOR TREATING B CELL PROLIFERATIVE DISORDERS | CORNELL UNIVERSITY (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015073833-A1 | METHODS FOR DELAYING OR PREVENTING THE ONSET OF TYPE 1 DIABETES | PHARMACYCLICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150141438-A1 | METHODS FOR DELAYING OR PREVENTING THE ONSET OF TYPE 1 DIABETES | VANDERBILT UNIVERSITY | 2015-05-21 | — | — | US | disclosed |
| US-20150141438-A1 | METHODS FOR DELAYING OR PREVENTING THE ONSET OF TYPE 1 DIABETES | VANDERBILT UNIVERSITY | 2015-05-21 | — | — | US | disclosed |
| US-20150118222-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150118222-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC | 2015-04-30 | — | — | US | disclosed |
| WO-2015061751-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061752-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20150118209-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-20150118209-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121463-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | ITK 28/4885LCK 65/4885TXK 9/4885 |
| US-20150118222-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | BTK, LCK, LYN | ITK 97/4885LCK 2/4885TXK 108/4885 |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | ITK 372/4885LCK 24/4885TXK 1842/4885 |
| US-20150118209-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | ITK 28/4885LCK 65/4885TXK 9/4885 |
| US-20210177854-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | ITK 748/4885LCK 278/4885TXK 475/4885 |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | CD47, LTK, PBK | ITK 1196/4885LCK 61/4885TXK 2215/4885 |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | PBK, LTK, CD47 | ITK 770/4885LCK 55/4885TXK 1644/4885 |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | ITK 748/4885LCK 278/4885TXK 475/4885 |
| US-20150141438-A1 | METHODS FOR DELAYING OR PREVENTING THE ONSET OF TYPE 1 DIABETES | IAPP, IRS1, CD22 | ITK 1418/4885LCK 197/4885TXK 1246/4885 |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | ICOS, PBK, IL2 | ITK 83/4885LCK 12/4885TXK 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.